# Hemophilia Treatment and Research

**Type:** Topics  
**Canonical URL:** https://scholariq.org/topics/hemophilia-treatment-and-research/

## Facts

| Field | Value |
| --- | --- |
| Description | This cluster of papers focuses on the management and treatment of hemophilia, including prophylaxis, inhibitors, gene therapy, and the impact on joint health. It covers a wide range of topics such as recombinant factor VIII, factor IX, and the safety and efficacy of various treatment strategies. |
| Domain | Health Sciences |
| Field | Medicine |
| OpenAlex ID | t11280 |
| Works | 86 |

## Topic papers all

Showing 15 of 86.

- [Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia](https://scholariq.org/papers/prophylaxis-versus-episodic-treatment-to-prevent-joint-disease-in-boys-with/)
- [EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update](https://scholariq.org/papers/eular-recommendations-for-the-management-of-rheumatoid-arthritis-with-synthetic-3/)
- [The Ratio of Blood Products Transfused Affects Mortality in Patients Receiving Massive Transfusions at a Combat Support Hospital](https://scholariq.org/papers/the-ratio-of-blood-products-transfused-affects-mortality-in-patients-receiving/)
- [Safety of Recombinant Activated Factor VII in Randomized Clinical Trials](https://scholariq.org/papers/safety-of-recombinant-activated-factor-vii-in-randomized-clinical-trials/)
- [2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema](https://scholariq.org/papers/2010-international-consensus-algorithm-for-the-diagnosis-therapy-and-management/)
- [Nonviral Transfer of the Gene Encoding Coagulation Factor VIII in Patients with Severe Hemophilia A](https://scholariq.org/papers/nonviral-transfer-of-the-gene-encoding-coagulation-factor-viii-in-patients-with/)
- [Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B](https://scholariq.org/papers/gene-therapy-with-etranacogene-dezaparvovec-for-hemophilia-b/)
- [Results of the CONTROL Trial: Efficacy and Safety of Recombinant Activated Factor VII in the Management of Refractory Traumatic Hemorrhage](https://scholariq.org/papers/results-of-the-control-trial-efficacy-and-safety-of-recombinant-activated-factor/)
- [Hemostasis and Thrombosis](https://scholariq.org/papers/hemostasis-and-thrombosis/)
- [Factor VIIa for Correction of Traumatic Coagulopathy](https://scholariq.org/papers/factor-viia-for-correction-of-traumatic-coagulopathy/)
- [Safety and Efficacy of Recombinant Activated Factor VII](https://scholariq.org/papers/safety-and-efficacy-of-recombinant-activated-factor-vii/)
- [Efficacy of Prothrombin-Complex Concentrates in Hemophiliacs with Antibodies to Factor VIII](https://scholariq.org/papers/efficacy-of-prothrombin-complex-concentrates-in-hemophiliacs-with-antibodies-to/)
- [International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency](https://scholariq.org/papers/international-consensus-and-practical-guidelines-on-the-gynecologic-and/)
- [The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients](https://scholariq.org/papers/the-many-roles-of-tranexamic-acid-an-overview-of-the-clinical-indications-for/)
- [Multiple-Ligament Knee Injuries: A Systematic Review of the Timing of Operative Intervention and Postoperative Rehabilitation](https://scholariq.org/papers/multiple-ligament-knee-injuries-a-systematic-review-of-the-timing-of-operative/)

## Topic primary papers

Showing 15 of 51.

- [Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia](https://scholariq.org/papers/prophylaxis-versus-episodic-treatment-to-prevent-joint-disease-in-boys-with/)
- [Safety of Recombinant Activated Factor VII in Randomized Clinical Trials](https://scholariq.org/papers/safety-of-recombinant-activated-factor-vii-in-randomized-clinical-trials/)
- [Nonviral Transfer of the Gene Encoding Coagulation Factor VIII in Patients with Severe Hemophilia A](https://scholariq.org/papers/nonviral-transfer-of-the-gene-encoding-coagulation-factor-viii-in-patients-with/)
- [Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B](https://scholariq.org/papers/gene-therapy-with-etranacogene-dezaparvovec-for-hemophilia-b/)
- [Results of the CONTROL Trial: Efficacy and Safety of Recombinant Activated Factor VII in the Management of Refractory Traumatic Hemorrhage](https://scholariq.org/papers/results-of-the-control-trial-efficacy-and-safety-of-recombinant-activated-factor/)
- [Factor VIIa for Correction of Traumatic Coagulopathy](https://scholariq.org/papers/factor-viia-for-correction-of-traumatic-coagulopathy/)
- [Safety and Efficacy of Recombinant Activated Factor VII](https://scholariq.org/papers/safety-and-efficacy-of-recombinant-activated-factor-vii/)
- [Efficacy of Prothrombin-Complex Concentrates in Hemophiliacs with Antibodies to Factor VIII](https://scholariq.org/papers/efficacy-of-prothrombin-complex-concentrates-in-hemophiliacs-with-antibodies-to/)
- [The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients](https://scholariq.org/papers/the-many-roles-of-tranexamic-acid-an-overview-of-the-clinical-indications-for/)
- [Recombinant Activated Factor VII in Cardiac Surgery: A Systematic Review](https://scholariq.org/papers/recombinant-activated-factor-vii-in-cardiac-surgery-a-systematic-review/)
- [Burden of illness: direct and indirect costs among persons with hemophilia A in the United States](https://scholariq.org/papers/burden-of-illness-direct-and-indirect-costs-among-persons-with-hemophilia-a-in/)
- [FVIII production by human lung microvascular endothelial cells](https://scholariq.org/papers/fviii-production-by-human-lung-microvascular-endothelial-cells/)
- [Guidelines for the use of recombinant activated factor VII in massive obstetric haemorrhage](https://scholariq.org/papers/guidelines-for-the-use-of-recombinant-activated-factor-vii-in-massive-obstetric/)
- [Etranacogene Dezaparvovec: First Approval](https://scholariq.org/papers/etranacogene-dezaparvovec-first-approval/)
- [A cross-sectional analysis of cardiovascular disease in the hemophilia population](https://scholariq.org/papers/a-cross-sectional-analysis-of-cardiovascular-disease-in-the-hemophilia/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.